Literature DB >> 25696274

Enhancing reverse cholesterol transport/raising HDL cholesterol: new options for prevention and treatment of cardiovascular disease.

J W Jukema, M Lenselink, G J de Grooth, S M Boekholdt, A H Liem, J-A Kuivenhoven, J J P Kastelein.   

Abstract

High-density lipoprotein cholesterol (HDL-c) plays a crucial role in the concept of reverse cholesterol transport and has many other beneficial properties which may interfere with atherogenesis and plaque rupture. Low HDL-c levels are currently considered to be an important risk factor for the development of cardiovascular disease. However until recently no effective and safe treatment for powerfully increasing HDL-c selectively was available. This short overview describes possible new therapeutic approaches that may be able to raise HDL-c levels or improve HDL-c metabolism/reverse cholesterol transport. Today, the most important targets to be evaluated are inhibition of cholesteryl ester transfer protein (CETP) and increasing the HDL-c level by infusion of engineered HDL particles. Trials to prove clinical benefit of new HDL-c raising approaches are underway and may well be a new starting point for an optimised prevention and treatment of atherosclerotic cardiovascular disease.

Entities:  

Keywords:  HDL; cardiovascular disease; cholesterol; prevention; transport; treatment

Year:  2004        PMID: 25696274      PMCID: PMC2497410     

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  50 in total

Review 1.  Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.

Authors:  C E Rackley
Journal:  Clin Cardiol       Date:  1996-09       Impact factor: 2.882

2.  Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity.

Authors:  K Hirano; S Yamashita; N Nakajima; T Arai; T Maruyama; Y Yoshida; M Ishigami; N Sakai; K Kameda-Takemura; Y Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-06       Impact factor: 8.311

3.  Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels.

Authors:  K F Kozarsky; M H Donahee; A Rigotti; S N Iqbal; E R Edelman; M Krieger
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

Review 4.  The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.

Authors:  J A Kuivenhoven; H Pritchard; J Hill; J Frohlich; G Assmann; J Kastelein
Journal:  J Lipid Res       Date:  1997-02       Impact factor: 5.922

5.  Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation.

Authors:  T Z Naqvi; P K Shah; P A Ivey; M D Molloy; A M Thomas; S Panicker; A Ahmed; B Cercek; S Kaul
Journal:  Am J Cardiol       Date:  1999-11-01       Impact factor: 2.778

6.  A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.

Authors:  H Okamoto; F Yonemori; K Wakitani; T Minowa; K Maeda; H Shinkai
Journal:  Nature       Date:  2000-07-13       Impact factor: 49.962

7.  A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism.

Authors:  A Rigotti; B L Trigatti; M Penman; H Rayburn; J Herz; M Krieger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

8.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

9.  Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism.

Authors:  Ke Ma; Mehmet Cilingiroglu; James D Otvos; Christie M Ballantyne; Ali J Marian; Lawrence Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-24       Impact factor: 11.205

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  1 in total

1.  Comparative Structures and Evolution of Vertebrate Carboxyl Ester Lipase (CEL) Genes and Proteins with a Major Role in Reverse Cholesterol Transport.

Authors:  Roger S Holmes; Laura A Cox
Journal:  Cholesterol       Date:  2011-11-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.